Evidence map›Paper›PMID 26912947›Full record

ArticleTrends in cancer research

Molecular basis of differentiation therapy for soft tissue sarcomas.

Gaurav Luther, Richard Rames, Eric R Wagner, Gaohui Zhu, Qing Luo, Yang Bi, Stephanie H Kim, Jian-Li Gao, Enyi Huang, Ke Yang and 12 more

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in Trends in cancer research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact, top 59% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 2 institutions in 1 country.

Gaurav LutherMolecular Oncology Laboratory, Department of Surgery, The University of Chicago Medical Center, Chicago, IL 60637, USA.
Richard RamesMolecular Oncology Laboratory, Department of Surgery, The University of Chicago Medical Center, Chicago, IL 60637, USA.
Eric R WagnerMolecular Oncology Laboratory, Department of Surgery, The University of Chicago Medical Center, Chicago, IL 60637, USA.
Gaohui ZhuMolecular Oncology Laboratory, Department of Surgery, The University of Chicago Medical Center, Chicago, IL 60637, USA; Stem Cell Biology and Therapy Laboratory, The Children's Hospital of Chongqing Medical University, Chongqing 400014, China.
Qing LuoMolecular Oncology Laboratory, Department of Surgery, The University of Chicago Medical Center, Chicago, IL 60637, USA; Stem Cell Biology and Therapy Laboratory, The Children's Hospital of Chongqing Medical University, Chongqing 400014, China.
Yang BiMolecular Oncology Laboratory, Department of Surgery, The University of Chicago Medical Center, Chicago, IL 60637, USA; Stem Cell Biology and Therapy Laboratory, The Children's Hospital of Chongqing Medical University, Chongqing 400014, China.
Stephanie H KimMolecular Oncology Laboratory, Department of Surgery, The University of Chicago Medical Center, Chicago, IL 60637, USA.
Jian-Li GaoMolecular Oncology Laboratory, Department of Surgery, The University of Chicago Medical Center, Chicago, IL 60637, USA; Key Laboratory of Diagnostic Medicine designated by Chinese Ministry of Education and Affiliated Hospitals, Chongqing Medical University, Chongqing 400016, China.
Enyi HuangMolecular Oncology Laboratory, Department of Surgery, The University of Chicago Medical Center, Chicago, IL 60637, USA; School of Bioengineering, Chongqing University, Chongqing 400044, China.
Ke YangMolecular Oncology Laboratory, Department of Surgery, The University of Chicago Medical Center, Chicago, IL 60637, USA; Department of Cell Biology, The Third Military Medical University, Chongqing 400030, China.
Linyuan WangMolecular Oncology Laboratory, Department of Surgery, The University of Chicago Medical Center, Chicago, IL 60637, USA.
Xing LiuMolecular Oncology Laboratory, Department of Surgery, The University of Chicago Medical Center, Chicago, IL 60637, USA; Stem Cell Biology and Therapy Laboratory, The Children's Hospital of Chongqing Medical University, Chongqing 400014, China.
Mi LiMolecular Oncology Laboratory, Department of Surgery, The University of Chicago Medical Center, Chicago, IL 60637, USA; Stem Cell Biology and Therapy Laboratory, The Children's Hospital of Chongqing Medical University, Chongqing 400014, China.
Ning HuMolecular Oncology Laboratory, Department of Surgery, The University of Chicago Medical Center, Chicago, IL 60637, USA; Key Laboratory of Diagnostic Medicine designated by Chinese Ministry of Education and Affiliated Hospitals, Chongqing Medical University, Chongqing 400016, China.
Yuxi SuMolecular Oncology Laboratory, Department of Surgery, The University of Chicago Medical Center, Chicago, IL 60637, USA; Stem Cell Biology and Therapy Laboratory, The Children's Hospital of Chongqing Medical University, Chongqing 400014, China.
Xiaoji LuoMolecular Oncology Laboratory, Department of Surgery, The University of Chicago Medical Center, Chicago, IL 60637, USA; Key Laboratory of Diagnostic Medicine designated by Chinese Ministry of Education and Affiliated Hospitals, Chongqing Medical University, Chongqing 400016, China.
Liang ChenMolecular Oncology Laboratory, Department of Surgery, The University of Chicago Medical Center, Chicago, IL 60637, USA; Key Laboratory of Diagnostic Medicine designated by Chinese Ministry of Education and Affiliated Hospitals, Chongqing Medical University, Chongqing 400016, China.
Jinyong LuoMolecular Oncology Laboratory, Department of Surgery, The University of Chicago Medical Center, Chicago, IL 60637, USA; Key Laboratory of Diagnostic Medicine designated by Chinese Ministry of Education and Affiliated Hospitals, Chongqing Medical University, Chongqing 400016, China.
Rex C HaydonMolecular Oncology Laboratory, Department of Surgery, The University of Chicago Medical Center, Chicago, IL 60637, USA.
Hue H LuuMolecular Oncology Laboratory, Department of Surgery, The University of Chicago Medical Center, Chicago, IL 60637, USA.
Lan ZhouMolecular Oncology Laboratory, Department of Surgery, The University of Chicago Medical Center, Chicago, IL 60637, USA; Key Laboratory of Diagnostic Medicine designated by Chinese Ministry of Education and Affiliated Hospitals, Chongqing Medical University, Chongqing 400016, China.
Tong-Chuan HeMolecular Oncology Laboratory, Department of Surgery, The University of Chicago Medical Center, Chicago, IL 60637, USA; Stem Cell Biology and Therapy Laboratory, The Children's Hospital of Chongqing Medical University, Chongqing 400014, China; Key Laboratory of Diagnostic Medicine designated by Chinese Ministry of Education and Affiliated Hospitals, Chongqing Medical University, Chongqing 400016, China.
University of Chicago Medical Center · USMolecular Oncology (United States) · US

Funding

Regulation of beta-Catenin Signaling by Tyrosine PhosphorylationR01CA106569 · NCI · UNIVERSITY OF CHICAGO · PI HE, TONG-CHUAN · 2006 to 2010
$1.3M
BMP6-Mediated OsteogenesisK08AR050142 · NIAMS · UNIVERSITY OF CHICAGO · PI HAYDON, REX C · 2004 to 2008
$596k
The role of connective Tissue Growth Factor on BMP9-Induced OsteogenesisK08AR054381 · NIAMS · UNIVERSITY OF CHICAGO · PI LUU, HUE HAN · 2007 to 2011
$595k
NCI NIH HHS L30 CA104199NCI NIH HHS L40 CA123669NCI NIH HHS R01 CA106569NIAMS NIH HHS K08 AR050142NIAMS NIH HHS K08 AR054381
6 · The paper itself

Abstract

Stem cells are undifferentiated precursor cells with the capacity for proliferation or terminal differentiation. Progression down the differentiation cascade results in a loss of proliferative potential in exchange for the differentiated phenotype. This balance is tightly regulated in the physiologic state. Recent studies, however, have demonstrated that during tumorigenesis, disruptions preventing terminal differentiation allow cancer cells to maintain a proliferative, precursor cell phenotype. Current therapies (i.e., chemotherapy and radiation therapy) target the actively proliferating cells in tumor masses, which in many cases inevitably induce therapy-resistant cancer cells. It is conceivable that promising therapy regimens can be developed by treating human cancers by inducing terminal differentiation, thereby restoring the interrupted pathway and shifting the balance from proliferation to differentiation. For example, osteosarcoma (OS) is a primary bone cancer caused by differentiation defects in mesenchymal stem cells (MSCs) for which several differentiation therapies have shown great promise. In this review, we discuss the various differentiation therapies in the treatment of human sarcomas with a focus on OS. Such therapies hold great promise as they not only inhibit tumorigenesis, but also avoid the adverse effects associated with conventional chemotherapy regimens. Furthermore, it is conceivable that a combination of conventional therapies with differentiation therapy should significantly improve anticancer efficacy and reduce drug-resistance in the clinical management of human cancers, including sarcomas.

Indexed as

differentiation therapylineage-specific differentiationMesenchymal stem cellsOsteosarcomasarcomagenesisSarcomassoft tissue tumorstumorigenesis

Identifiers

PMID26912947
PMCPMC4762605
OpenAlexW2490745574

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.